

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete If Known

Application Number	09/619,493
Filing Date	July 19, 2000
First Named Inventor	N. NASHED et al.
Group Art Unit	1818
Examiner Name	S.N. Qazi
Attorney Docket Number	SCH 1686 C1

~~OCT 15~~ 2003

TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	<i>Sabiha Qayyum</i>	Date Considered	7/6/04
-----------------------	----------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. SCH 1686C1		APPLICATION SERIAL NO. 09/619,493	
<div style="border: 2px solid black; border-radius: 50%; padding: 10px; display: inline-block;"> O I P E SEP 25 2001 PATENT & TRADEMARK OFFICE </div>				APPLICANT Norman NASHED			
				FILING DATE July 19, 2000		GROUP 1616	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
SOP	AA	5,583,129	12/1996	Spona et al.			RECEIVED SEP 26 2001 TECH CENTER 1600/2900
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
SOP	AL	0 640 343 A	3/1/1995	EPO			
	AM	43 13 926 A	11/3/1994	GERMANY			
	AN	43 44 462 A	6/29/1995	GERMANY			
	AO						
	AP						
	AQ						
	AR						
	AS						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	El-Sherbini, Abbas (CA 82:68681, abstract of Aln Shams Med, J. (1974), 25(4), 579-85), 1974.					
SOP	AU	Boekler, H. (CA 78:24468, abstract of Sportarzt sportmad. (1972), 22(9), 233-4, 236-7, 1972.					
	AV	Neuman, Friedmund (CA 118:161077, abstract of Pharm. Ztg. (1992), 137(34), 9-15), 1992.					
	AW	Guenther et al. (CA 113:218253, abstract of WO 9004397), 1974.					
	AX	L.L. Altshuler et al.: "Pharmacological management of premenstrual disorder." HARVARD REV. PSYCHIAT., BD 2 nR. 5, 1995, pages 233-245					
Examiner				Date Considered			
Sabiha Qzz				7/7/04			

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/619,493
Filing Date	July 19, 2000
First Named Inventor	N. Nashed et al.
Group Art Unit	1616
Examiner Name	S. Qazi
Attorney Docket Number	SCH 1686 C1

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

RECEIVED

APR 25 2002



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/619,493
Filing Date	July 19, 2000
First Named Inventor	N. Nashed et al.
Group Art Unit	1616
Examiner Name	S. Qazi
Attorney Docket Number	SCH 1686 C1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	BL	Christine P. West, "Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome," European Journal of Obstetrics & Gynecology and Reproductive Biology, 34 (1990), pp. 119-128	
	BM	C. Kirkham, MD., et al., "A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy," Obstetrics & Gynecology, Vol. 78, No. 1, July 1991, pp. 93-97	
	BN	L. Dennerstein, et al., "Progesterone and premenstrual syndrome: a double blind crossover trial," British Medical Journal, Vol. 290, June 1, 1985, pp. 1617-1621	
	BO	Peter J. Schmidt, MD., et al., "Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome," The New England Journal of Medicine, Vol. 324, No. 17, April 25, 1991, pp. 1174-1179	
SON	BP	John Bancroft et al., "The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, Food Craving and Other Symptoms," Journal of Psychosomatic Research, Vol. 37, No. 2, 1993, pp. 195-202	
	BQ	Cynthia A. Graham, et al., "A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral Contraceptive," Journal of Psychosomatic Research, Vol. 36, No. 3, 1992, pp. 257-268	
	BR	Lennart Nilsson et al., "Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4 Different Preparations (Anovlar® mite, Lyndiol® mite, Ovulen®, and Volidan®)," Acta Obstetrichet Gynecologica Scandinavica, Vol. XLVI, Supplement 8, pp. 2-31 yr. 1967.	
	BS	Johan Cullberg, "Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations," Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86	
	BT	Sam Silbergeld, Ph.D., MD., et al., "The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Biochemical Variables Using Enovid and Placebo," Psychosomatic Medicine, Vol. 33, No. 5 (Sept-Oct 1971), pp. 411-428	
	BU	Francis J. Kane, "Iatrogenic Depression in Women," Phenomenology and Treatment of Depression, Copyright 1977, pp. 69-81	

Examiner
Signature

SABHA QAZI

Date

Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

APR 25 2002

TECH CENTER



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/619,493
Filing Date	July 19, 2000
First Named Inventor	N. Nashed et al.
Group Art Unit	1616
Examiner Name	S. Qazi
Attorney Docket Number	SCH 1686 C1

TECH CENTER 1600/2900

APR 25 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDZ	BA	Mabray et al., "Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures," Obstetrics & Gynecology, Vol. 59, No. 5, May 1982, pp. 560-564	
	BB	B.P. Appleby, "A Study of Premenstrual Tension in General Practice," British Medical Journal, 2/6/60, pp. 391-393	
	BC	Stuart L. Smith, "Mood and Menstrual Cycle," pp. 19-59 <i>Incomplete</i>	
SDZ	BD	B. Andersch et al., "Progesterone Treatment of Premenstrual Tension-A Double Blind Study," Journal of Psychosomatic Research, Vol. 29, No. 5, 1985, pp. 489-493	
	BE	Michael A. Richter, M.D., et al., "Progesterone Treatment of Premenstrual Syndrome," Current Therapeutic Research, Vol. 36, No. 5, Nov. 1984, pp. 840-850	
	BF	Gwyneth A Sampson, "Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo," Brit. J. Psychiat. (1979), 135, 209-215	
	BG	Sarah Maddocks, et al., "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome," Am J Obstet Gynecol, March 1988, pp. 573-581	
	BH	Ellen Freeman, et al., "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome," JAMA, Vol. 264, No. 3, July 18, 1990, pp. 349-353	
	BI	Lorraine Dennerstein, et al., "Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone," Journal of Affective Disorders, 11 (1986), pp-199-205	
	BJ	Gwyneth A. Sampson, et al., "Premenstrual Syndrome A Double-blind Cross-over Study of Treatment with Dydrogesterone and Placebo," British Journal of Psychiatry, 153 (1988), pp. 232-235 ✓	
	BK	Pekka Ylostalo, et al., "Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome," Obstetrics & Gynecology, Vol. 58, No. 3, March, 1982, pp. 292-298	

Examiner Signature	SABITA QAZI	Date Considered	11/15/02
--------------------	-------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.